TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04743141: Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Sponsor: Pfizer · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$4,683,160

Rescue Site Savings

+$3,085,376

Unlock Full NCT04743141 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04743141 Rescue Dossier →